First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results - First Tracks (NASDAQ:TR

TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.

Raccontata dabenzinga.com